Nurix Therapeutics Inc (NRIX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $25.06 (-1.73%), Market cap $1.70B, 52-week low–high $8.24 ~ $21.47.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B
Financial statements, price targets, institutional (13F) holdings and related news for Nurix Therapeutics Inc are updated in real time on BlackAll Trade.
Nurix Therapeutics Inc trades at $25.06 (-1.73%). Real-time quotes and charts are available on BlackAll Trade.
Nurix Therapeutics Inc has a market cap of about $1.70B.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer,